export const diseaseInfoSections = [
  {
    title: "PID Overview",
    content: "PID is a lifelong immune system disease with unclear etiology and an incidence rate of about 0.01%. Diagnosis is relatively straightforward, requiring only symptom assessment in immunology outpatient clinics. Treatment is primarily outpatient-based."
  },
  {
    title: "Disease Severity",
    content: [
      "30% mild cases",
      "70% moderate to severe cases",
      "Random disease progression",
      "Current medications can only slow progression",
      "Surgical intervention may be needed for complications",
      "High patient compliance due to disease severity"
    ]
  },
  {
    title: "Treatment Evolution",
    content: "Before 2016, PID treatment relied on oral hormones and immunosuppressants. While fast-acting and low-cost, these carried risks of malignant tumors, cardiovascular issues, and severe infections."
  },
  {
    title: "Drug A (Ogano monoclonal antibody)",
    content: [
      "Approved in 2021 for moderate-severe PID",
      "100mg/injection, subcutaneous every 4 weeks",
      "IL9 pathway target",
      "70% response rate at 2 weeks, 80% at 8 weeks",
      "Price: ¥1,000/injection"
    ]
  },
  {
    title: "Drug D (Dengbixi monoclonal antibody)",
    content: [
      "Approved in 2023 for moderate-severe PID",
      "150mg/injection, subcutaneous every 12 weeks",
      "IL40 pathway target",
      "90% response rate at 8 weeks, maintained at 96 weeks",
      "Price: ¥2,500/injection"
    ]
  }
] as const;